- Home
- NKTR vs JCE Comparison
NKTR vs JCE Comparison
Compare NKTR & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- JCE
- Stock Information
- Founded
- NKTR 1990
- JCE 2007
- Country
- NKTR United States
- JCE United States
- Employees
- NKTR N/A
- JCE N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- JCE Trusts Except Educational Religious and Charitable
- Sector
- NKTR Health Care
- JCE Finance
- Exchange
- NKTR Nasdaq
- JCE Nasdaq
- Market Cap
- NKTR 108.3M
- JCE 253.3M
- IPO Year
- NKTR 1994
- JCE N/A
- Fundamental
- Price
- NKTR $24.76
- JCE $15.46
- Analyst Decision
- NKTR Strong Buy
- JCE
- Analyst Count
- NKTR 6
- JCE 0
- Target Price
- NKTR $77.50
- JCE N/A
- AVG Volume (30 Days)
- NKTR 4.6M
- JCE 49.7K
- Earning Date
- NKTR 08-07-2025
- JCE 01-01-0001
- Dividend Yield
- NKTR N/A
- JCE 9.26%
- EPS Growth
- NKTR N/A
- JCE N/A
- EPS
- NKTR N/A
- JCE N/A
- Revenue
- NKTR $87,248,000.00
- JCE N/A
- Revenue This Year
- NKTR N/A
- JCE N/A
- Revenue Next Year
- NKTR N/A
- JCE N/A
- P/E Ratio
- NKTR N/A
- JCE N/A
- Revenue Growth
- NKTR N/A
- JCE N/A
- 52 Week Low
- NKTR $6.48
- JCE $11.64
- 52 Week High
- NKTR $37.38
- JCE $14.28
- Technical
- Relative Strength Index (RSI)
- NKTR 68.00
- JCE 64.08
- Support Level
- NKTR $8.27
- JCE $14.36
- Resistance Level
- NKTR $26.59
- JCE $15.55
- Average True Range (ATR)
- NKTR 3.71
- JCE 0.26
- MACD
- NKTR 1.18
- JCE 0.05
- Stochastic Oscillator
- NKTR 57.06
- JCE 93.28
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.